Loading organizations...

§ Private Profile · Cambridge, MA, USA
Odyssey Therapeutics is a technology company.
Odyssey Therapeutics is a clinical-stage biopharmaceutical company developing novel small molecule therapies for serious autoimmune, inflammatory, and cancer diseases. It operates with a replicable, scalable model for drug development, utilizing robust capabilities in small molecule discovery to address complex biological targets and deliver therapeutic solutions.
Founded in 2021 by Gary D. Glick, Ph.D., a distinguished serial biotechnology entrepreneur, Odyssey Therapeutics benefits from his extensive track record. Dr. Glick previously established successful ventures like IFM Therapeutics, Scorpion Therapeutics, and Lycera Corporation. His founding insight was to create an efficient platform for rapid drug discovery, translating scientific advancements into impactful patient therapies.
The company serves patients afflicted with debilitating autoimmune, inflammatory, and oncological diseases. Odyssey Therapeutics' mission is to achieve substantial improvements in patient outcomes and elevate the standard of care for individuals facing these conditions, remaining dedicated to rigorous scientific innovation.
Odyssey Therapeutics has raised $700.0M across 4 funding rounds.
Odyssey Therapeutics has raised $700.0M in total across 4 funding rounds.
Odyssey Therapeutics is a clinical-stage biopharmaceutical company developing small molecule and protein therapeutics to treat autoimmune and inflammatory diseases by targeting upstream signaling in the innate immune system.[1][2] It addresses unmet needs in conditions like ulcerative colitis, rheumatoid arthritis, and Crohn's disease, with its lead program OD-07656—a RIPK2 inhibitor—set to enter Phase 2a trials in 2025 and 2026, serving patients seeking deeper remission beyond current standards.[1][2][3] Backed by experienced drug hunters and a scalable drug discovery model, Odyssey employs 151 people and focuses on precise pathology targeting in large patient populations.[1][4]
Founded in 2021 in Boston, Massachusetts, Odyssey emerged from a vision to redefine inflammatory disease treatment through novel immune system targeting.[1][2][5] Led by CEO Gary D. Glick, Ph.D., a seasoned biotech leader, the company assembled a team of "drug hunters" with expertise in immunology, medicinal chemistry, and structural biology, including key executives like COO Julie Clauss, CFO Jason Haas, and board chair Jeffrey M. Leiden, M.D., Ph.D.[1][2][4] Early traction came from prioritizing validated targets in high-need areas like IBD and oncology, rapidly advancing programs toward the clinic with backing from top investors like Catalio Capital, marking pivotal momentum in a competitive biotech landscape.[3]
Odyssey stands out in biotech through:
Odyssey rides the wave of precision immunology, capitalizing on advances in structural biology and AI-driven discovery to tackle "intractable" inflammatory conditions amid rising autoimmune disease prevalence.[2][3][5] Timing aligns with post-pandemic demand for safer, more effective therapies beyond biologics like vedolizumab, in a $100B+ market for IBD and arthritis where novel mechanisms promise differentiation.[1][3] It influences the ecosystem by validating novel drugging strategies, attracting syndicate funding, and accelerating clinical shots-on-goal, potentially reshaping standards for large patient populations.[3][4]
Odyssey's near-term catalysts—Phase 2a data readouts starting Q1 2025—could validate its immune-targeting bet, fueling pipeline expansion into oncology and more autoimmune indications.[1][3] Trends like AI integration in drug design and combo therapies will amplify its edge, with potential for partnerships or acquisitions as remission-focused drugs gain traction.[2][5] Its influence may grow by pioneering upstream interventions, evolving from clinical-stage player to transformative force in biotech, ultimately delivering the "extraordinary leaps" in patient outcomes it promises.[4]
Odyssey Therapeutics has raised $700.0M in total across 4 funding rounds.
Odyssey Therapeutics's investors include Dimension Capital, General Catalyst, OrbiMed, SR One, Third Rock Ventures, Rafaèle Tordjman, Shelley Chu, Paulina Hill, Carolyn Ng, Affinity Asset Advisors, Wedbush Healthcare Partners, Lorence Kim.
Odyssey Therapeutics has raised $700.0M across 4 funding rounds. Most recently, it raised $210.0M Series D in September 2025.